Atlas Trials

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

Clinical trial NCT07598448 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07598448
Sponsor
Novartis Pharmaceuticals
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Complement 3 Glomerulopathy
Start date
2026-08-23
Primary completion
2026-12-15
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.